delta-Opioid receptor agonists as a therapeutic
approach in Parkinson's disease
by
Hill MP, Hille CJ, Brotchie JM.
Motac Neuroscience Ltd.,
Incubator Building, Grafton St.,
Manchester, UK.
Drug News Perspect. 2000 Jun;13(5):261-8

ABSTRACT

Current symptomatic treatments for Parkinson's disease are based largely on dopamine replacement therapies; however, the fact that these treatments are characterized by many long-term side effects has led to widespread interest in nondopaminergic therapies. To date, a nondopaminergic therapy with comparable efficacy to dopamine replacement has not been devised. Here the authors discuss recent findings that systemic administration of a selective delta-opioid receptor agonist has powerful antiparkinsonian effects in rodent and primate models of Parkinson's disease that are equivalent to those of dopamine replacement. delta-Opioid receptor agonists may prove to be useful for the symptomatic treatment of Parkinson's disease in humans.

Delta agonists
Learned helplessness
Enkephalinase inhibitors : RB801
Opioids, brain stimulation and reward
Cholecystokinin and delta opioid receptors
Delta opioid receptors, emotion and motivation
Delta-opioid receptor agonists as antidepressants?

Refs
HOME
HedWeb
BLTC Research
Designer Drugs
Paradise-Engineering
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?